About

Synapsis Labs is a pioneering medical AI company specializing in automated analysis of medical imaging modalities. We develop cutting-edge AI systems that transform diagnostic workflows, delivering precision and efficiency to healthcare providers worldwide.

Solution & Product

Sentinel - Mammography Analysis Module Our flagship mammography AI system provides comprehensive breast imaging analysis, supporting radiologists with automated detection and classification capabilities. Sentinel enhances screening efficiency while maintaining the highest diagnostic accuracy standards. Vision - X-Ray Chest Module Our chest X-ray analysis solution delivers rapid, reliable interpretation of thoracic imaging. Vision assists healthcare providers in identifying critical findings, streamlining diagnostic workflows, and improving patient care outcomes.

Innovation & Scalability

Our innovation stems from: - Exam‐to‐Exam Comparison: Match current exam results with previous ones to track progress over time. - Multi-Modal Integration: Incorporate data from various exam modalities and deliver a unified final result. - Automated Impressions (Reporting): Ready made report for the doctor describing the findings and their anatomical location. - Seamless Adoption: Plug n Play on any vendor.

Traction & achievements

- 12.5% Greek mammography market share with €220K ARR in signed deals, demonstrating strong local market penetration and validation of our AI-powered diagnostic solutions - Strategic pharmaceutical partnerships including active discussions with Pfizer for European market expansion, positioning Synapsis for international growth opportunities - Scientific collaboration with Iatropolis providing access to >3.7PB of imaging data and >20 radiology specialists on our R&D team for continuous innovation and clinical validation - €1M seed round at €4.0M pre-money valuation with €250K already committed from leading investors, demonstrating strong market confidence and financial backing - 80M Euro EU expansion opportunity identified with clear pathway to 25% market share target by Q1 2027, supported by affiliate and client-based growth strategies - High-margin business model with 80% profit margins, pay-as-you-go and subscription pricing.

Team & Why Us

Leadership Team Synapsis Labs is led by a multidisciplinary team with deep expertise spanning healthcare technology, enterprise sales, and strategic operations. Angelos Roussakis | CEO | BSc Computer Science Applying fintech expertise in data systems, scalability, and innovation to transform healthcare technology. Proven track record in building robust, high-volume processing systems capable of handling 400+ medical exams per hour with enterprise-grade reliability. John Doulamis | Chief Sales Officer | BSc Computer Science Seasoned sales expert in healthcare industry with extensive experience across hospitals and diagnostic clinics. Instrumental in achieving 12.5% Greek market share and driving €220K ARR in signed deals through strategic customer engagement and market development. Clinical & Scientific Excellence Strategic Advisory Board: Sokratis Gourlis - CEO of Iatropolis Providing strategic healthcare industry guidance Mixalis Gakis - Renowned European radiologist practicing at Iatropolis Ensuring clinical accuracy and workflow integration Giorgos Pakos - Managing Partner at GU Group Driving growth strategy and market expansion

Funding Needs

Currently Synapsis is raising 1 M Euro which will be used within for the : - propelling its EU expansion and strengthening its position - establishing a strong global network of resellers - integrating software platform AI optimizations